User:Mr. Ibrahem/Luspatercept

Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of low red blood cells in beta thalassemia and myelodysplastic syndrome (MDS). In MDS it is used for cases in which the risk of blood cancer is no more than moderate and erythropoietin does not work. It is given by injection under the skin.

Common side effects include tiredness, headache, muscle pain, dizziness, nausea, cough, and allergic reactions. Other side effects may include blood clots and high blood pressure. Use in pregnancy may harm the baby. It is an erythroid maturation agent which works by blocking SMAD2 and SMAD3 pathways.

Luspatercept was approved for medical use in the United States in 2019 and Europe in 2020. In the United States it costs about 11,000 USD for 75 mg as of 2021. In Canada this amount costs about 6,600 CAD. While it is approved in the United Kingdom and Europe it is not currently available there as of 2021.